Introduction
Cimetidine has been reported to inhibit the cytochrome P-450 mediated oxidative metabolism of many drugs [7] . Since both cimetidine and butorphanol undergo Butorphanol tartrate is a synthetic opioid agonistantagonist analgesic. Although butorphanol is welloxidative metabolism in humans, it is possible that clearance of one or both drugs may be compromised absorbed orally, it undergoes extensive first-pass metabolism with an oral bioavailability of approximately 5% when the two compounds are administered simultaneously. This study was designed to define the extent (unpublished data). A nasal formulation of butorphanol was developed for convenient administration, avoidance of pharmacokinetic interaction between butorphanol nasal spray and cimetidine. of hepatic first-pass elimination, and rapid absorption. The absolute bioavailability of butorphanol nasal spray in humans is 70% [1] [2] [3] . Clinical trials have demonstrated that transnasal butorphanol provides rapid, effective analgesia with side effects comparable with Methods those seen after intramuscular or intravenous injection of the drug [ 4, 5] . Subjects Butorphanol is extensively metabolized with only small amounts of unchanged butorphanol excreted in Sixteen healthy male subjects reviewed and signed an informed consent form prior to participation in the the urine. The known metabolites of butorphanol are hydroxy-butorphanol, norbutorphanol, and the glucustudy. The study protocol was approved by the Institute Review Board of the clinical site. The key selection ronide conjugates of butorphanol and its two oxidation products [6 ] . Following intravenous dosing, about 80% criteria were that subjects did not have acute or chronic diseases, subjects had normal nasal anatomy and of the dose is recovered in the urine with approximately 30% accounted for by these compounds. mucosa, and did not suffer from nasal allergy or viral rhinitis. For Treatment A, the subjects had a mean Cimetidine is one of the most commonly prescribed medications for the treatment of duodenal ulcers.
(±s.d.) age of 29 (±6) years (range 20-37 years), a mean height of 178.0 (±7.3) cm (range 166.4-191.8 cm), and a additional urine sample was collected on day 12, 6-12 h post-dose. Plasma and urine samples were stored at mean body weight of 77.7 (±8.8) kg (range 64.5-88.6 kg). For Treatment B, the subjects had a mean (±s. [11 ] . Quality control samples were prepared Study design prior to the initiation of the study, stored and analysed at the same time as the study samples. The performance This was an open label, parallel, multiple dose study. Sixteen male subjects were randomly divided into two of the assays was acceptable based on the results of the estimated precision (<15% coefficient of variation) and treatment groups. Eight subjects (Treatment A) received a 1 mg dose of butorphanol nasal spray every 6 h on accuracy (<13% deviation) of the quality control samples. days 1-11 and a 300 mg dose of cimetidine every 6 h on days 5-8. On day 12, they received only a single 1 mg dose of butorphanol nasal spray. The other eight subjects (Treatment B) received a 300 mg dose of Pharmacokinetic analyses cimetidine tablet every 6 h on days 1-11 and a 1 mg dose of butorphanol nasal spray every 6 h on days 5-8.
Noncompartmental pharmacokinetic parameters were calculated as described previously [12, 13] . The highest On day 12, they received only a single 300 mg dose of cimetidine. Serial blood samples and the total urine observed concentration and the corresponding sampling time were defined as C max and t max , respectively. The output of each subject were collected for 6 h on days 4, 8 and 12 following the 08.00 h morning dose. Additional absolute value of the slope () of the concentration vs time log-linear regression function was used to determine blood and urine samples were collected for up to 12 h post-dose on day 12. Samples for the measurement of the terminal elimination half-life as using the equation t D =ln 2/l. The area under the concentration vs time trough concentrations (C min ) were also collected on days 3, 7 and 11, immediately before the morning dose.
curve (AUC (0-t)) was calculated using the trapezoidal rule. Mean residence time in the body at steady state (MRT), renal clearance (CL R ) and urinary recovery (%UR) values were calculated using standard methods Drug administration [12, 13] . The percentage of the dose recovered as metabolites was calculated by correcting for the differEach dose of butorphanol nasal spray dose was administered in one spray (approximately 0.1 ml of a ence in molecular weight between butorphanol and each metabolite. 10 mg ml−1 solution) into one nostril. Each subject was instructed and familiarised in the use of the sprayer and during the studies the drug was self-administered. Cimetidine tablets (300 mg) were administered with Statistical analyses 200 ml of water. During the co-administration period, cimetidine administration occurred within 5 min of the Repeated measures analysis was conducted on C max , t max , t D , AUC (0−t), MRT, CL R and %UR within the administration of butorphanol nasal spray. Subjects fasted overnight on days 3, 7 and 11, on the days blood treatment. For each study treatment, the above parameters were compared at the three sampling periods using was sampled.
the a one-way analysis of variance. In the case of t max , its rank transformation was used for the analysis. C min values were compared in the same way to demonstrate Sample collection the attainment of steady state. The subject and day effects were estimated using Type III sums of squares. Blood samples were collected at pre-dose, 5, 15, 30, and 45 min, and 1, 1.5, 2, 3, 4, and 6 h after dosing, on days Significance of the subject and day effects was determined using the mean square error term. If the effect of days 4, 8 and 12. Additional blood samples were collected at 8, 10 and 12 h after dosing on study day 12. On days 3, was statistically significant, Tukey's procedure was used to make pairwise comparisons based on the means. 7 and 11, a blood sample was drawn prior to administration of the morning dose. Urine samples were Additionally, 95% confidence intervals for differences in means were calculated based on the Tukey's procedure. collected over the following time intervals: pre-dose, 0-2, 2-4, and 4-6 h post-dose on days 4, 8 and 12. An Levene's test was used to check the assumption of homogeneity of variance among sampling times [14 ] . state was achieved within 3 days of dosing. No statistical difference was found in any of the butorphanol pharm-A two-sample t-statistic was used to compare the treatments with respect to the individual pharmacoacokinetic parameters before (day 4 ), during (day 8 ) or after (day 12) the co-administration of cimetidine. The kinetics of cimetidine and butorphanol obtained from the second sampling (day 8). The value P=0.05 was 95% confidence intervals for differences in means are presented in Table 1 . Less than 25% of the administered used as the significance level for all tests except Levene's test, where P=0.001 was used.
dose was excreted in urine as either unchanged butorphanol or its metabolites. There was a modest increase (<3%) in the recovery of each analyte after the hydrolysis of the urine samples, suggesting that glucuronidation of butorphanol and its metabolites is minimal.
Results
No statistically significant differences in the pharmacokinetics of butorphanol on day 8 were observed between Safety groups assigned to either butorphanol or cimetidine treatment. Butorphanol and cimetidine were well tolerated. A total of 82 adverse experiences were reported by 12 subjects. Sixty-three events were reported by the butorphanol T reatment B No statistical difference was found in C max , T max , AUC (0−t), CL R and %UR of cimetidine group (Treatment A) and 19 events were reported by the cimetidine group (Treatment B). The most combefore (day 4), during (day 8 ) or after (day 12) the co-administration of butorphanol. The mean C max and monly experienced adverse events were lightheadedness (38%), rash (7%), queasy stomach (6%), nausea (5%) AUC(0−t) values in the 3 different days ranged from 1.55-1.83 mg ml−1 and 6.60-7.05 mg ml−1 h, respectively. and backache (5%). The temperature, blood pressure, pulse, ECG, clinical laboratory and nasal examination
The mean values for CL R and %UR were about 133-162 ml.min−1 and 18-21%, respectively. The t max results were similar before, during and after the study period. No significant changes were observed at anytime was usually achieved in 1.5-2.0 h after dosing. The mean values of t D and MRT on day 8, during the during the study.
co-administration of cimetidine and butorphanol, were statistically greater (P<0.008) than those observed on days 4 and 12.
The mean values of t D and MRT Pharmacokinetics increased from 2.47 h to3.89h and from 4.23 to 6.57 h, respectively. There were no statistical differences T reatment A The mean (s.d.) values for pharmacokinetic parameters of butorphanol are presented in observed in the C min data comparisons, day 3 vs day 4, day 7 vs day 8, and, day 11 vs day 12, suggesting that Table 1 . There were no statistical differences observed in the C min data comparisons, day 3 vs day 4, day 7 vs steady state was achieved within 3 days of dosing.
No statistically significant differences were found in day 8, and, day 11 vs day 12, suggesting that steady Table 1 Mean (s.d.) pharmacokinetic parameters for butorphanol in subjects receiving repeated 1 mg dose of butorphanol by nasal spray (n=8) with (day 8 ) or without (days 4 and 12) the coadministration of oral cimetidine ( Treatment A). In Treatment B, subjects received butorphanol on day 8 Mean plasma concentration -time profiles of butorphanol in subjects who received 1 mg butorphanol by nasal spray before (study day 1), during (study day 8 ) and after (study day 12) the co-administration of oral cimetidine (300 mg every 6 h).
the pharmacokinetics of cimetidine on day 8 between References groups assigned to either butorphanol or cimetidine treatment. The results from this study indicate that the pharmaco- P450 [15] . The lack of a significant pharmacokinetic when these drugs are co-administered by these routes. hydroxybutorphanol, and norbutorphanol in human urine
